Detailed price information for Werewolf Therapeutics Inc (HOWL-Q) from The Globe and Mail including charting and trades.

Detailed price information for Werewolf Therapeutics Inc (HOWL-Q) from The Globe and Mail including charting and trades.

Werewolf Therapeutics ... The Company is leveraging its proprietary PREDATOR ® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the ...

Werewolf Therapeutics ... The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the ...

Wedbush reissued their outperform rating on shares of Werewolf Therapeutics (NASDAQ:HOWL – Free Report) in a report issued on Wednesday morning, Marketbeat Ratings reports. They currently have a $8.00 ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination ...

Reports Q4 revenue $0 vs. $301,590. “Werewolf made considerable progress in 2024 with promising preliminary evidence of durable anti-tumor ...

The deal is also a first partnership focusing on Werewolf's PREDATOR protein engineering platform, which also includes IL-2 (WTX-124) and IL-12 (WTX-330) candidates preclinical development.

Werewolf Therapeutics provided a business update ... of WTX-124 in the fourth quarter of 2025. In addition, our PREDATOR platform continues to demonstrate its effectiveness as we presented ...

"Werewolf made considerable progress in 2024 with promising preliminary evidence ... providing an update on our plans for further clinical development of WTX-124 in the fourth quarter of 2025. In ...